Chugai files lawsuit against Alexion for infringement of its proprietary antibody engineering technology in Japan

Chugai files lawsuit against Alexion for infringement of its proprietary antibody engineering technology in Japan


Chugai Pharmaceutical Co., Ltd. announced that it has filed a patent infringement lawsuit at the

 

 

Tokyo District Court as follows.

Date of Complaint: December 5, 2018

Reasons for the Action: Chugai alleges that the anti-C5 antibody ALXN1210 (ravulizumab) product, an investigational drug developed by Alexion Pharma Godo Kaisha (Japan Regional Headquarters), infringes some of its Japan patents (Patent No. 4954326 and No. 6417431) relating to its proprietary antibody engineering technology. Thus, Chugai filed a patent infringement lawsuit against Alexion requesting a judgment that the ALXN1210 product infringes Chugai’s Japan patent and injunctive relief precluding manufacturing and selling of the ALXN1210 product in Japan.

Defendant Name: Alexion Pharma Godo Kaisha

Address: 18-14 Ebisu 1-Chome, Shibuya-ku, Tokyo, JAPAN

Prospects No changes are expected to be made to Chugai’s financial prospects at this point.

Key Facts
    •  News CategoryIntellectual Property
      Legal And Regulatory
      Other Product News
      Product Development
    •  CompanyAlexion Pharmaceuticals Inc Chugai Pharmaceutical Co Ltd
    •  CountryAsia-Pacific > Japan
      North America > United States of America

Leave a Reply

Your email address will not be published. Required fields are marked *

99 − = 97

Did you find this content engaging?